Glioblastoma and Glioblastoma Multiforme (GBM)
Telix Pharmaceuticals (Innovations) Pty Limited focuses its clinical research on aggressive primary brain tumours, with a particular emphasis on glioblastoma and glioblastoma multiforme. The studies it supports are centred on patients with newly diagnosed disease and those with recurrent disease.
- Recurrent glioblastoma
- Newly diagnosed glioblastoma
- Glioblastoma multiforme (GBM)
The sponsor’s trial portfolio reflects sustained interest in treatment settings where disease control and survival outcomes remain major clinical challenges.
Oncology and Neuro-oncology
The sponsor’s research activity is concentrated in oncology, with a clear therapeutic focus on neuro-oncology and malignancies of the central nervous system. Its funded trials address tumour management in the brain, where therapeutic options are limited and clinical need is high.
- Central nervous system cancer
- Brain tumour therapy
- Neuro-oncology treatment development
Clinical activity is distributed across multiple collaborating sites and countries, supporting research in specialised cancer care settings.
Radiopharmaceutical and Targeted Cancer Therapy
Telix Pharmaceuticals is actively involved in trials exploring radiopharmaceutical-based approaches for tumour treatment, including targeted strategies designed for brain cancer. The research landscape includes investigational therapies used alongside established standard of care regimens.
- Radiopharmaceutical therapy
- Targeted tumour treatment
- Combination cancer therapy
These studies place emphasis on treatment selection in difficult-to-manage glioma populations.
Survival Outcomes and Treatment Tolerability
The trials funded by the sponsor are directed toward key clinical endpoints in glioblastoma, including overall survival, safety, tolerability, and dose selection in patients with recurrent or newly diagnosed disease.
- Overall survival
- Safety and tolerability
- Dose optimisation
Research sites are engaged in evaluating therapeutic options intended for high-risk brain tumour populations.
